JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on OPT stock, giving a Buy rating on February 28.
Debanjana Chatterjee’s rating is based on Opthea Limited’s promising clinical trial results and financial stability. The company is on track with its Phase 3 trials, COAST and ShORe, which are expected to provide significant data in early and mid-2025. These trials involve the combination of sozinibercept with aflibercept and ranibizumab, respectively. Despite some speculation about the superiority of aflibercept over ranibizumab, there is confidence that sozinibercept can demonstrate meaningful vision improvement, especially when combined with aflibercept.
Furthermore, Opthea’s financial position is robust, with $131.9 million in cash and equivalents, providing a runway into the third quarter of 2025. The company’s strategic financial planning, including adjusted expense estimates and non-cash interest projections, supports its growth trajectory. The potential for a Biologics License Application (BLA) filing in the first half of 2026 and a possible U.S. launch in 2027 further strengthens the Buy rating, with a price target set at $13.
In another report released on February 28, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.